Zynex (OTCMKTS:ZYXI) has been given a $7.00 price objective by investment analysts at B. Riley in a research note issued to investors on Friday, November 2nd. The brokerage presently has a “buy” rating on the stock. B. Riley’s price objective suggests a potential upside of 112.12% from the stock’s current price.
Several other brokerages also recently commented on ZYXI. ValuEngine downgraded shares of Zynex from a “hold” rating to a “sell” rating in a report on Friday, August 3rd. Zacks Investment Research downgraded shares of Zynex from a “hold” rating to a “sell” rating in a report on Friday, August 10th.
Shares of ZYXI traded down $0.12 on Friday, hitting $3.30. 12,059 shares of the stock traded hands, compared to its average volume of 16,615. Zynex has a one year low of $1.10 and a one year high of $5.50. The company has a market capitalization of $109.83 million, a P/E ratio of 15.00 and a beta of 0.95.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.